New drug trial aims to tame painful joint and skin disease

NCT ID NCT04314531

Ongoing Disease control Sponsor: Sun Pharmaceutical Industries Limited Source: ClinicalTrials.gov ↗

Summary

This study is testing whether an injectable drug called tildrakizumab can safely reduce symptoms of active psoriatic arthritis. It will involve about 296 adults with the condition who have not previously tried a common class of arthritis drugs (anti-TNFs). Participants will receive either the real drug or a placebo to compare how well it works at reducing joint pain, swelling, and skin symptoms.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Sunpharma Site 100

Madrid, 28046, Spain
Sunpharma Site 106

Lucknow, Uttar Pradesh, 226003, India
Sunpharma Site 107

Belagavi, Karnataka, 590016, India
Sunpharma Site 108

Pune, Maharashtra, 411004, India
Sunpharma Site 109

Hubli, Karnataka, 580021, India
Sunpharma Site 110

Bangalore, Karnataka, 560079, India
Sunpharma Site 111

Surat, Gujarat, 395010, India
Sunpharma Site 112

Hyderabad, Telangana, 500003, India
Sunpharma Site 113

Kochi, 682040, India
Sunpharma Site 18

Incheon, 22332, South Korea
Sunpharma Site 19

Seoul, 4763, South Korea
Sunpharma Site 20

Seoul, 3080, South Korea
Sunpharma Site 22

Kitakyushu-shi, 802-8561, Japan
Sunpharma Site 23

Tsu, 514-8507, Japan
Sunpharma Site 24

Miyazaki, Miyazaki, 889-1692, Japan
Sunpharma Site 39

Phillip, Australian Capital Territory, 2606, Australia
Sunpharma Site 63

Zlín, 760 01, Czechia
Sunpharma Site 64

Brno, 638 00, Czechia
Sunpharma Site 71

Córdoba, 14004, Spain
Sunpharma Site 72

Seville, 41013, Spain
Sunpharma Site 73

Berlin, 12161, Germany
Sunpharma Site 74

Poznan, 61-113, Poland
Sunpharma Site 75

A Coruña, 15006, Spain
Sunpharma Site 84

Nagoya, Aichi-ken, 467-0001, Japan
Sunpharma Site 85

Shinjuku, Tokyo, 160-0023, Japan
Sunpharma Site 86

Sendai, Miyagi, 980-8574, Japan
Sunpharma Site 87

Osaka, 545-0051, Japan
Sunpharma Site 88

Kumamoto, 860-8556, Japan
Sunpharma Site 89

Kitakyushu, Fukuoka, 802-8561, Japan
Sunpharma Site 90

tabashi City, Tokyo, 173-8606, Japan
Sunpharma Site 91

Mitaka, Tokyo, 181-8611, Japan
Sunpharma Site 92

Herne, 44649, Germany
Sunpharma Site 93

Bialystok, 15-351, Poland
Sunpharma Site 94

Lublin, 20-607, Poland
Sunpharma Site 95

Bialystok, 15-879, Poland
Sunpharma Site 96

Warsaw, 02-118, Poland
Sunpharma Site 97

Prague, 12800, Czechia
Sunpharma site no. 01

Tomball, Texas, 77375, United States
Sunpharma site no. 02

New Port Richey, Florida, 34652, United States
Sunpharma site no. 03

San Antonio, Texas, 78229, United States
Sunpharma site no. 04

Miami Beach, Florida, 33140, United States
Sunpharma site no. 05

Springfield, Missouri, 65810, United States
Sunpharma site no. 06

Spokane, Washington, 99204, United States
Sunpharma site no. 07

Tamarac, Florida, 33321, United States
Sunpharma site no. 08

Hobart, Tasmania, 7000, Australia
Sunpharma site no. 09

Lubbock, Texas, 79410, United States
Sunpharma site no. 10

Lincoln, Nebraska, 68516, United States
Sunpharma site no. 11

Greenville, South Carolina, 29601, United States
Sunpharma site no. 12

Covina, California, 91722, United States

Conditions

Explore the condition pages connected to this study.

ACTIVE PSORIATIC ARTHRITIS